GlassScriptPhysician profile
David M Abdehou
NPI 1568471993
$7,931.53
in general payments reported to CMS, 2019-2025
42 companies · $859 in 2025
The $859 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $666 · 2021: $1,517 · 2022: $1,951 · 2023: $1,581 · 2024: $896 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,336.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,345.85 | 2019-2024 | Injectafer |
| Abbvie INC. | $515.39 | 2021-2025 | Ubrelvy |
| Novo Nordisk INC | $401.80 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $365.94 | 2019-2025 | |
| Lilly USA, LLC | $360.56 | 2020-2025 | Mounjaro, Zepbound |
| Paratek Pharmaceuticals, INC. | $360.51 | 2020-2023 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $356.54 | 2019-2024 | Airsupra, Breztri |
| Acadia Pharmaceuticals INC | $304.72 | 2019-2023 | Nuplazid |
| Glaxosmithkline, LLC. | $262.16 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $243.53 | 2020-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.92 | 2021-2025 | Jardiance |
| Amgen INC. | $218.98 | 2020-2025 | Evenity, Krystexxa, Prolia |
| Otsuka America Pharmaceutical, INC. | $185.91 | 2023-2025 | Rexulti, Nuedexta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.52 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $146.14 | 2021-2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $132.75 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $131.48 | 2022-2025 | Myrbetriq, Veozah |
| Insmed, INC. | $124.47 | 2019 | |
| Axsome Therapeutics, INC. | $117.65 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $108.10 | 2020-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $104.56 | 2019-2021 | |
| Lundbeck LLC | $86.13 | 2023-2025 | Rexulti, Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $74.93 | 2022 | |
| Abbott Laboratories | $62.40 | 2022-2023 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $61.88 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $52.78 | 2021-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $40.95 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $39.09 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $37.92 | 2019-2020 | |
| Allergan, INC. | $36.72 | 2020 | |
| Eisai INC. | $34.70 | 2021 | |
| Itamar Medical INC | $34.30 | 2023 | Watchpatone |
| Phathom Pharmaceuticals, INC. | $23.14 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $22.95 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $22.83 | 2023 | |
| Exact Sciences Corporation | $20.07 | 2024 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $19.71 | 2022 | |
| Ethicon US, LLC | $17.84 | 2021 | |
| Cvrx, INC. | $16.63 | 2024 | Barostim Neo System |
| Mallinckrodt Hospital Products INC. | $15.87 | 2023 | Terlivaz |
| Arbor Pharmaceuticals, INC. | $14.12 | 2022 | |
| Ibsa Pharma INC. | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Abdehou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.